

Interview Summary	Application No. 09/902,266	Applicant(s) De LACHARRIERE et al.
	Examiner Michele Flood	Group Art Unit 1651

All participants (applicant, applicant's representative, PTO personnel):

(1) Michele Flood _____ (3) _____
 (2) Antoinette M. Lee (See Below) _____ (4) _____

Date of Interview Oct 31, 2002

Type: a) Telephonic b) Video Conference
 c) Personal [copy is given to 1) applicant 2) applicant's representative]

Exhibit shown or demonstration conducted: d) Yes e) No. If yes, brief description:

Claim(s) discussed: None

Identification of prior art discussed:

Agreement with respect to the claims f) was reached. g) was not reached. h) N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments:

Antoinette M. Lee, representative of Pharmacovigilance, a division of Bausch & Lomb, archived the OCUVITE (registered trademark) product cited in Drug Launches (3/23/1998) and confirmed that the product comprised Vitamin A in the form of beta-carotene at the time that the reference was published. The technical data of the product was facsimiled to the Office and is attached hereto.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

i) It is not necessary for applicant to provide a separate record of the substance of the interview (if box is checked).

Unless the paragraph above has been checked, THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.

old formula
OCUVITE® Vitamin and Mineral Supplement, Tablets

(Product Code 4550)

<u>Active Constituents</u>	Label Claim	Quantity/ Tablet (mg)	Percent Excess	Percent (w/w)
<u>Vitamins:</u>				
Vitamin A (as beta carotene)	5000 IU	20.250	35	3.022
Vitamin C (ascorbic acid)	60 mg	74.000	11	11.043
Vitamin E (as dl-alpha tocopheryl acetate)	30 IU	66.000	10	9.849
<u>Minerals:</u>				
Zinc (zinc oxide)	40 mg	54.767	10	8.173
Copper (cupric oxide)	2 mg	2.754	10	0.411
Selenium (sodium selenate)	40 mcg	0.144	50	0.022
<u>Other Constituents</u>				
Dibasic Calcium Phosphate USP		270.000		40.291
VITACEL (a)		134.229		20.030
Crospovidone NF		20.000		2.984
Magnesium Stearate NF		3.500		0.522
Silicon Dioxide NF (Sylloid 244)		3.000		0.447
Stearic Acid NF		1.500		0.224
<u>Film Coating Solvent Constituents</u>				
Triethyl Citrate		0.953		0.142
Polysorbate NF		0.572		0.085
Opadry Orange YS-1-9703 (b)		18.460		2.755
Purified Water (c)		0.000		

Each tablet contains less than 1 calorie

- (a) Contains 65 % Microcrystalline Cellulose and 35 % Calcium Carbonate
- (b) Opadry Orange YS-1-9703 contains the following: hydroxypropyl methylcellulose, titanium dioxide (E171), sodium lauryl sulfate, and FD&C Yellow No. 6.
- (c) Used in the manufacturing process but does not appear in final product.

updated March, 2000

Phone: 800-227-1427 ext. 2545
Fax: 813-975-7770

Bausch & Lomb

Fax

To: Michelle Flood

From: Antionette M. Lee

Fax: 703-746-5245

Date: October 31, 2002

Phone: 703-308-9432

Pages: 2

Re: Ocuvite

Urgent **For Review** **Please Comment** **Please Reply** **Please Recycle**

Comments:

This fax is in response to your phone call on October 31, 2002. We at Bausch & Lomb Pharmaceuticals, Inc. value hearing from our customers because product quality and customer satisfaction are important to us.

Thank you for your interest in our products. I hope this information is helpful to you.